STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
A Galleri advisory-committee vote, a Lilly approval and a radiopharma merger set the day's regulatory tone.
TL;DR
- STAT reported on what a vote on Grail's cancer detection test — the Galleri test, before an FDA advisory committee — could mean for the company, patients and regulators.
- STAT also reported that Lilly's breast cancer combination won approval, and that two radiopharma companies merged after one received a surprise FDA rejection.
- A medRxiv pilot study from Thailand examined urine DNA methylation as a diagnostic and surveillance tool in bladder cancer.
STAT reported on what a vote on Grail's cancer detection test — the Galleri test, before an FDA advisory committee — could mean for the company, patients and regulators. [1]
STAT also reported that Lilly's breast cancer combination won approval, and that two radiopharma companies merged after one received a surprise FDA rejection. [2] [3]
Separately, a medRxiv pilot study from Thailand examined urine DNA methylation as a potential diagnostic and surveillance tool in non-muscle invasive bladder cancer. [4]
Why it matters
Screening tests and approvals are where diagnostics and drug economics meet, so regulatory decisions on tests like Galleri shape both patient access and the companies' commercial runway.
Editor's note
Regulatory and approval details are as reported by STAT and were not independently verified; the bladder-cancer study is a pilot and is labeled as such. No medical advice is offered.